Digi International Bolsters Digi Connect EZ Family of Device Servers with Launch of 8/16/32 Port Options
6.4.2023 15:00:00 EEST | Business Wire | Press release
Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the launch of Digi Connect® EZ 8/16/32. This solution represents the latest in Digi’s line of next-generation device servers providing secure, scalable connectivity for business, commercial, and industrial automation applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005005/en/
Digi Connect EZ 8/16/32 comes with a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support. (Photo: Business Wire)
The product expansion underscores Digi’s commitment to supporting critical industries spanning utilities, energy, aerospace, government, commercial, logistics and factory automation with intelligent end-to-end serial connectivity solutions. Combining state-of-the-art hardware with the robust Digi Accelerated Linux (DAL) operating system, the Digi Connect EZ 8/16/32 line offers a range of industry-leading features. These include cellular support and the unparalleled central management capabilities of Digi Remote Manager® (Digi RM). This platform enables in-depth, 360-degree visibility to configure, deploy, and manage remote assets securely.
Also included with Digi Connect EZ 8/16/32 is a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support.
“We are excited to expand the Digi Connect EZ family, providing enhanced solutions and devices that enable our customers to conveniently and securely scale their operations today, while preemptively addressing the IIoT challenges of tomorrow,” said Brian Kirkendall, General Manager and Vice President of Infrastructure Management at Digi. “The incorporation and availability of our wider product features such as cellular support, central management with Digi RM, and round-the-clock expert assistance underscore Digi’s ongoing commitment to supporting customers throughout the entire product lifecycle.”
Hardware-enabled and software-defined, the Connect EZ family of products delivers a scalable solution that supports multiple serial interfaces in both industrial and non-industrial environments. Digi Connect EZ prevents data loss, providing state of the art communication technology to meet the needs of machine-to-machine serial communication customers all over the world. Additionally, the Connect EZ family offers an updated hardware platform that ensures longevity, manageability, and deployment flexibility. To manage critical serially connected equipment at scale, the Connect EZ family adheres to the following key attributes:
- Scalability — Simple click-to-connect deployment using Digi Navigator, with quick configuration providing easy integration for a wide range of use cases. Digi Connect EZ is truly easy to deploy and manage at scale throughout the product lifecycle with robust security, management and device health capabilities.
- Reliability — Built on top of the Digi TrustFence® design architecture and DAL operating system, Digi Connect EZ is designed for deployment in industrial environments to offer a secure, stable, and resilient platform for mission-critical connectivity, including LTE and Wi-Fi.
- Capability — Supports a wide range of industry standard and device-specific protocols using serial tunneling, and TCP/UDP connections or Digi’s patented RealPort® COM port redirector for remote native COM port access. Additionally, the built-in Python environment enables application development and customization at the device level, including event-based programmability, data conversion and full control of device connections.
“No matter the industry, no matter the challenge — from industrial automation to large scale manufacturing to secure communication of critical data — we’ve got our customers covered,” Kirkendall continued. “With the Connect EZ 8/16/32 expansion, we’re delivering the scalable and secure end-to-end connectivity solution our customers not only need, but that they deserve.”
Availability
Digi Connect EZ® 8/16/32 devices are available for immediate purchase now.
Explore the solutions here:
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005005/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom